Literature DB >> 15491286

Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.

Hong Chang1, Stephen Sloan, Dan Li, A Keith Stewart.   

Abstract

Central nervous system (CNS) involvement is an unusual manifestation in multiple myeloma (MM). The molecular basis of CNS myeloma is poorly understood. MM is characterized by translocations involving the immunoglobulin heavy chain (IgH) locus and frequent 13q deletions. Alterations of p53 or c-myc in MM may represent secondary changes associated with disease progression. We investigated nine patients with CNS MM using interphase fluorescence in situ hybridization (FISH) combined with immunofluorescence detection of the cytoplasmic light chain (cIg-FISH) for the presence of above genomic aberrations. Of nine patients studied, eight cases had hemizygous p53 deletion and 4 had 13q deletions. Of the patients with 13q deletions, two had IgH translocations, one involving 4p16.3 (FGFR3), the other involving 16q23 (c-maf). The high incidence of p53 deletions detected by cIg-FISH in CNS myeloma may be a marker for chromosomal instability, and may be associated with metastatic features of myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491286     DOI: 10.1111/j.1365-2141.2004.05199.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  27 in total

1.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Mark R Litzow; Kimberly J Henderson; Scott A Van Wier; Greg J Ahmann; Rafael Fonseca
Journal:  Blood       Date:  2005-06-23       Impact factor: 22.113

2.  Identification of transmembrane protein 88 (TMEM88) as a dishevelled-binding protein.

Authors:  Ho-Jin Lee; David Finkelstein; Xiaofeng Li; Dianqing Wu; De-Li Shi; Jie J Zheng
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

3.  Intracranial mass of multiple myeloma with good response to chemotherapy.

Authors:  Nathalie E Synhaeve; Cees van der Heul; Cees C Tijssen
Journal:  BMJ Case Rep       Date:  2012-09-30

4.  Adult-onset adrenoleukodystrophy presenting after chemotherapy: No black and white matter.

Authors:  David Isaacs; Inan Olmez; Daniel O Claassen
Journal:  Neurol Clin Pract       Date:  2014-04

Review 5.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

Review 6.  How We Manage Patients with Plasmacytomas.

Authors:  Despina Fotiou; Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

7.  Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.

Authors:  Wenjun Yu; Jianyong Li; Lijuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

8.  Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Authors:  Artur Jurczyszyn; Norbert Grzasko; Alessandro Gozzetti; Jacek Czepiel; Alfonso Cerase; Vania Hungria; Edvan Crusoe; Ana Luiza Miranda Silva Dias; Ravi Vij; Mark A Fiala; Jo Caers; Leo Rasche; Ajay K Nooka; Sagar Lonial; David H Vesole; Sandhya Philip; Shane Gangatharan; Agnieszka Druzd-Sitek; Jan Walewski; Alessandro Corso; Federica Cocito; Marie-Christine M Vekemans; Erden Atilla; Meral Beksac; Xavier Leleu; Julio Davila; Ashraf Badros; Ekta Aneja; Niels Abildgaard; Efstathios Kastritis; Dorotea Fantl; Natalia Schutz; Tomas Pika; Aleksandra Butrym; Magdalena Olszewska-Szopa; Lidia Usnarska-Zubkiewicz; Saad Z Usmani; Hareth Nahi; Chor S Chim; Chaim Shustik; Krzysztof Madry; Suzanne Lentzsch; Alina Swiderska; Grzegorz Helbig; Renata Guzicka-Kazimierczak; Nikoletta Lendvai; Anders Waage; Kristian T Andersen; Hirokazu Murakami; Sonja Zweegman; Jorge J Castillo
Journal:  Am J Hematol       Date:  2016-04-24       Impact factor: 10.047

Review 9.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

Review 10.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.